by Mark Curtis | Nov 20, 2014
. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its...
by Ben Paylor | Oct 24, 2014
> Just over one year ago, we launched the pilot phase of an animation project titled StemCellShorts here on Signals blog. Funded by a Stem Cell Network Public Outreach Award, the project was very much an experiment for us to see what would happen when you tasked a...
by Holly Wobma | Oct 6, 2014
> “Wow, my mouth just got diabetes.” Such are my immediate thoughts after taking a bite out of a red velvet cupcake. Though I must qualify: by cupcake, I mean a skyscraper of frosting carefully balanced on a minimal crumbly foundation. Making such a hyperbolic...
by Lisa Willemse | Sep 19, 2014
> There are a multitude of ways to stay informed about research trends and advances in the field. Obvious ones, for a researcher or trainee are lab or journal club meetings, conferences, or journal subscriptions. Then there’s the online world, including any...
by Mark Curtis | Aug 18, 2014
. Welcome to your Update from the Clinic for the month of July. The cancer stem cell companies were back in the news last month. OncoMed initiated its ALPINE clinical trial of Tarextumab for pancreatic cancer, while Stemline Therapeutics announced an investigational...
Comments